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Abstract
Background: Severe acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) is
a common reason for emergency room (ER) visit about which little has been documented from
India.
Methods: Prospective study of the clinical presentation and predictors of outcome in 116 patients
presenting with severe AE-COPD requiring admission to the medical intensive care unit between
January 2000 and December 2004.
Results: Their mean age was 62.1 ± 9.8 years. There were 102 males. Mean duration of COPD
was 7.2 ± 5.8 years. All males were smokers (22.3 ± 11.2 pack years); 35.2% smoked cigarettes and
64.8% smoked bidis. All women were exposed to domestic fuel. Associated co-morbid illnesses
were present in 81 patients (69.8%); 53(45.7%) had one co-morbid illness and the remaining 28
(54.3%) had two or more co-morbid illnesses. Evidence of past pulmonary tuberculosis (PTB) was
present in 28.4% patients; 5 patients who also had type II diabetes mellitus had active PTB. Arterial
blood gas analysis revealed respiratory failure in 40 (33.8%) patients (type I 17.5% and type II
82.5%). Invasive mechanical ventilation was required in 18 patients. Sixteen (13.7%) patients died.
Stepwise multivariate logistic regression analysis revealed need for invasive ventilation (OR 45.809,
95%CI 607.46 to 3.009;p < 0.001); presence of co-morbid illness (OR 0.126, 95%CI 0.428 to
0.037;p < 0.01) and hypercapnia (OR 0.114, 95%CI 1.324 to 0.010;p < 0.05) were predictors of
death.
Conclusion: Co-morbid conditions and metabolic abnormalities render the diagnosis of AE-
COPD difficult and also contribute to mortality. High prevalence of past PTB and active PTB in
patients with AE-COPD suggests an intriguing relationship between smoking, PTB and COPD
which merits further study.
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Background
Chronic obstructive pulmonary disease (COPD), a com-
mon, costly and preventable disease and is the fourth
leading cause of death globally [1,2]. Internationally there
is a substantial variation in death rate due to COPD pos-
sibly reflecting smoking behaviour, type and processing of
tobacco, pollution, climate, and genetic factors. Given the
fact that there is an increasing tendency to abuse tobacco
[3-6], prevalence of COPD is expected to increase in the
years to come. Acute exacerbation of COPD (AE-COPD) is
a common cause of emergency room (ER) visits and is a
major cause of morbidity and mortality. Following an
acute exacerbation, majority of the patients experience a
temporary or permanent decrease in the quality of life [7].
Moreover, more than half the patients discharged with
AE-COPD often require re-admission in the subsequent
six months [7]. Thus, the economic and social burden of
AE-COPD are extremely high [1]. The great variability in
the course of AE-COPD even in patients with similar
degree of pulmonary impairment renders the prediction
of the outcome in a given patient very difficult. Most stud-
ies have tried to correlate impairment in both respiratory
and non-respiratory physiology with the course and pro-
gression of the AE-COPD with inconclusive results.
Though AE-COPD is a common reason for ER visits, little
has been documented about this problem from India.
Furthermore, even less data are available from India
regarding the prevalence, precipitating factors and predic-
tors of prognosis in patients with AE-COPD. Even from
the developed world, while there are many published
studies regarding the prognostic factors among patients
with AE-COPD who are ambulatory, few studies have
examined the prognostic factors in patients with severe
AE-COPD who visit the ER and little is known regarding
the long-term prognosis of patients with AE-COPD [8].
Keeping these factors in mind, the present study was
designed to prospectively study the clinical presentation
and predictors of outcome in patients with AE-COPD
requiring admission to the intensive care unit (ICU).
Methods
During the period January 2000 to December 2004, 914
patients were diagnosed to have COPD and were treated
and followed-up from the Medicine Out-patient Depart-
ment and Chest Clinic of our tertiary care referral centre.
During the study period, 314 of them presented to our ER
with AE-COPD. Of these 314 patients, after initial stabili-
sation and management in the ER, 116 were admitted to
the medical ICU; 18 were discharged from the ER; and the
remaining 180 were admitted to the acute medical care
unit and the medical wards of the hospital. The predictors
for mortality were studied in the 116 patients who were
admitted to the medical ICU. Patients in whom the pri-
mary cause of ER visit was bronchiectasis, interstitial lung
disease, acute severe bronchial asthma, pulmonary edema
or pulmonary embolism were excluded from the study.
The study was approved by the institutional ethics com-
mittee.
In all of them, pulmonary function testing was done using
Morgan Transfer Test Benchmark PFT System (Morgan
Scientific, Inc. Haverhill, MA, USA) at the time of the ini-
tial out-patient visit and COPD was diagnosed based on
the criteria laid down by the American Thoracic Society
(ATS) [8] and post-bronchodilator forced expiratory vol-
ume in the first second to forced vital capacity (FEV1/FVC)
ratio less than or equal to 0.7 was documented in all of
them confirming the presence of airflow limitation that is
not fully reversible. They were all receiving a combination
of various bronchodilators and anticholinergic agents.
AE-COPD was diagnosed if all of the following criteria
were present at the time of ER visit: (i) recent rapid wors-
ening of dyspnoea; (ii) increase in sputum purulence; and
(iii) increase in sputum volume. Patients were eligible for
only a single enrollment in this study. Hospital admis-
sions during the study period subsequent to the index
admission were not considered in the analysis.
In all of them, a detailed history was taken and a thorough
physical examination was done. These details were
recorded in a predesigned proforma. From the smoking
history, number of "pack years" was computed in cigarette
smokers from the average number of cigarettes smoked
per day, one pack year being smoking of 20 cigarettes per
day for one year. Since the net weight of tobacco in a bidi
(150 to 240 mg) is about one-fourth that in a cigarette
[9,10], in bidi smokers, "cigarette equivalent pack years"
were computed. This was arrived at by dividing the "pack
years" calculated on the basis of smoking bidis by four
[9,10]. History of exposure to domestic fuel was recorded
in female patients who were non-smokers.
At admission, in all the patients full haemogram, serum
biochemistry; urine analysis were performed. Sputum and
blood culture examination were performed to identify the
etiological cause. Other diagnostic investigations related
to the co-morbid illnesses and for monitoring the treat-
ment were performed where they were required. Depend-
ing upon the clinical condition of the patient, bed side
portable or postero-anterior view chest radiograph were
performed at admission. In all the patients, 12-lead elec-
trocardiogram (ECG) and echocardiography were per-
formed within 24 hours of admission after initial
stabilisation. Cor-pulmonale was diagnosed if there was
ECG (p-pulmonale; right axis deviation; right ventricular
hypertrophy) and echocardiographic evidence of right
ventricular hypertrophy/dilatation. Two ml of
heparinised blood sample was procured for arterial bloodBMC Pulmonary Medicine 2006, 6:27 http://www.biomedcentral.com/1471-2466/6/27
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gas (ABG) analysis from the radial artery and was trans-
ported to the laboratory immediately for processing. ABG
analysis was done using AVL Compact 2 (Radiometer,
Denmark) analyzer.
Oxygen was administered through a standard dual-prong
nasal cannula or face mask. When hypercapnia was a con-
cern, oxygen was delivered through a Venturi mask (main-
taining a fixed ratio of oxygen to room air). The oxygen
therapy was guided by the ABG report and oxygen satura-
tion (SaO2) measured using a pulse oximeter. Initially,
salbutamol (as frequently as 5 mg every 15 minutes to
every 8 hours) and ipratropium bromide (as frequently as
0.5 mg every 15 minutes to 0.5 mg every 8 hours) were
administered through an ultrasonic nebuliser. If the aero-
sol therapy proved inadequate, intravenous aminophyl-
line was administered using a constant volume infusion
pump. They received injectable corticosteroids (hydrocor-
tisone/methyl prednisolone) for 72 hours following
which oral prednisolone was administered in a dosage
0.75 mg/kg body weight for a subsequent period of seven
more days. Pharmacological treatment was optimized
based on the clinical response. Empirical antibiotic treat-
ment was initiated as appropriate in 104 patients (89.6%)
and the antibiotic choice was further modified basing on
the culture and sensitivity report.
Criteria for intubation were not standardized, and nonin-
vasive ventilation was infrequently utilized at our hospital
during the period of study. Endotracheal intubation and
assisted mechanical ventilation were initiated when phar-
macologic and other non-ventilatory treatments failed to
reverse clinically significant respiratory failure. Indica-
tions for initiating invasive mechanical ventilation
included any of the following: severe dyspnea with use of
accessory muscles and paradoxical abdominal motion;.
severe acidosis (pH < 7.25) and hypercapnia (PaCO2 > 60
mmHg); life-threatening hypoxaemia [arterial oxygen ten-
sion (PaO2)/inspiratory oxygen fraction (FIO2) < 200
mmHg)]; tachypnoea (>35 breaths/min); respiratory
arrest; somnolence, impaired mental status; presence of
co-morbid illness; and presence of other complications.
The associated co-morbid illnesses were monitored and
treated appropriately. Criteria for discharge from hospital
included patients clinically and ABG wise stable for 24
hours; inhaled β2-agonist therapy is required no more fre-
quently than every 4 hours; patient is able to eat and sleep
without frequent awakening by dyspnea [1].
Statistical Analysis
Variables following normal distribution were summa-
rized by mean and standard deviation. The association
between two categorical variables was evaluated by χ2 test
or Fisher's exact test as appropriate. Student's 't' test (for
normally distributed variables) was used to compare the
difference in mean values in the two groups for quantita-
tive variables. To determine various predictors of death
following hospitalization for AE-COPD, the analysis was
performed in two stages. For this purpose the quantitative
variables were categorized. Variables showing statistically
significant association with the outcome (death during in-
hospital stay) at p < 0.20, were considered as candidate
variables for inclusion in the multivariate model. Stepwise
multivariate logistic regression was performed with the
potential candidate variables as the co-variates. SYSTAT
version 7.0 (SPSS Inc., Chicago, USA) was used for data
analysis. All the statistical tests performed were two tailed;
p < 0.05 was considered as statistically significant.
Results
The mean age of the patients was 62.1 ± 9.8 years (Table
1); there were 102 males. Their demographic parameters,
smoking history, COPD staging based on pulmonary
function testing done prior to the present episode of ER
visit as per the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) staging [1] and details regarding
co-morbid conditions are depicted in Table 1. Majority of
the males (64.8%) smoked bidis. All women gave a his-
tory of exposure to domestic fuel such as dried cow dung
cakes, wood, dried coconut shells, crop residues and grass.
Evidence of past pulmonary TB was present in 28.4%
patients presenting with AE-COPD requiring admission
into the medical ICU (n = 116). In five of these patients
who also had type II diabetes mellitus, sputum smear-pos-
itive pulmonary TB was diagnosed at the time of present-
ing to the ER with AE-COPD. Three patients with type II
diabetes mellitus also had diabetic ketoacidosis. On com-
paring the prevalence of past pulmonary tuberculosis (TB)
among the 314 patients with AE-COPD (116 patients
with AE-COPD who were admitted to the medical ICU,
the 198 patients who presented to the ER, but who did not
require admission into the medical ICU) and the remain-
ing 600 patients who were on follow-up but who did not
develop AE-COPD, it was found that patients with past
pulmonary TB were more likely to suffer from AE-COPD
than those who did not have pulmonary TB (61 of 314 vs.
24 of 600; χ2 = 56.343, p < 0.001).
Table 2 depicts the clinical presentation of AE-COPD. All
the 15 of the 116 (12.9%) patients with altered sensorium
manifested one or more metabolic abnormalities
[hyponatremia (n = 9); hypokalemia (n = 7); hyperbiliru-
binemia (n = 3); elevated transaminases (n = 12) elevated
blood urea (n = 11); and elevated serum creatinine (n =
3)] or type II respiratory failure and carbon dioxide reten-
tion (n = 11). Cor-pulmonale was present in 23 (19.8%)
patients.BMC Pulmonary Medicine 2006, 6:27 http://www.biomedcentral.com/1471-2466/6/27
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Chest radiograph revealed infiltrates in 48 (41.4%)
patients; 33 had evidence of past pulmonary TB; 5
patients were diagnosed to have sputum smear-positive
pulmonary TB; in the remaining 10 patients, focal paren-
chymal infiltrates without air-bronchogram, suggestive of
lower respiratory tract infection were present and all these
10 patients had negative sputum and blood culture. None
of the five patients with AE-COPD who had active pulmo-
nary TB (n = 5) had any symptom or sign suggestive of
active TB when they last presented to the out-patient
department/chest clinic for follow-up. Furthermore, they
also did not have any past history of TB. Pulmonary TB
was diagnosed in them only at the time of the ER visit with
AE-COPD.
Laboratory abnormalities at initial presentation are
shown in Table 3. ABG analysis revealed respiratory fail-
ure in 40 (33.8%) patients; 7 (17.5%) manifested type I
and 33 (82.5%) patients manifested type II respiratory
failure. Bacterial isolates were grown in 25 (21.6%)
patients; in 11 (44%) patients, more than one pathogen
was isolated. Of these isolates, S. pneumoniae (42.9%) and
Klebsiella sp (35.7%) were the most common bacteria
isolated.
There was no statistically significant difference in the clin-
ical presentation and laboratory abnormalities between
smokers of bidi and cigarette. Invasive mechanical venti-
lation was required in 18 (15.5%) patients. Overall, 16
(13.7%) patients died. This included patients requiring
mechanical ventilation (n = 8), patients who had type II
diabetes mellitus and diabetic ketoacidosis (n = 3); type II
diabetes mellitus and active pulmonary TB (n = 5) at pres-
entation. The mean duration of in-hospital stay was 6.8 ±
6.6 days.
The predictors of in-hospital death in patients with AE-
COPD as per univariate sensitivity analysis and stepwise
multivariate logistic regression analysis are shown in
Tables 4 and 5 respectively. Type of smoking (cigarette vs.
bidi) did not influence the outcome (death). Stepwise
multivariate logistic regression analysis revealed need for
invasive ventilation (p < 0.001); presence of co-morbid
illness (p < 0.01) and hypercapnia (p < 0.05) were predic-
tors of death.
Discussion
Reliable epidemiological data regarding the burden of AE-
COPD in the ER are lacking from India. Even less is
Table 1: Demographic characteristics and co-morbid conditions in 116 patients with acute exacerbation of chronic obstructive 
pulmonary disease admitted to the medical intensive care unit
Age (years) (mean ± SD) 62.1 ± 9.8
Gender
Male 102
Female 14
Smoking (all males) 22.3 ± 11.2 pack years
Duration of symptoms (years) (mean ± SD) 7.6 ± 5.2
COPD, GOLD stage*
Moderate [No. (%)] 25 (21.6)
Severe [No. (%)] 55 (47.4)
Very severe [No. (%)] 36 (31.0)
Co-morbid conditions
Hypertension [No. (%)] 40 (34.5)
Alcoholism [No. (%)] 38 (32.8)
Type II diabetes mellitus [No. (%)] 36 (31.0) †
Past pulmonary tuberculosis [No. (%)] 33 (28.4) ‡
Coronary artery disease [No. (%)] 12 (10.3)
Chronic renal failure [No. (%)] 10 (08.6)
Number of co-morbid illnesses
0 [No. (%)] 35 (30.2)
1 [No. (%)] 53 (45.7)
2 [No. (%)] 18 (15.5)
3 [No. (%)] 07 (06.0)
4 [No. (%)] 03 (02.6)
GOLD = Global Initiative for Chronic Obstructive Lung Disease (reference 1)
COPD = chronic obstructive pulmonary disease
* In all patients post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) was ≤ 0.7. Moderately severe 
COPD, FEV1 = 50 – 80% predicted; severe COPD, FEV1 = 30 – 50% predicted; very severe COPD = <30% predicted (reference 1)
† 3 patients had diabetic ketoacidosis and 5 patients had active pulmonary tuberculosis
‡ Clinical and radiographic evidence of past tuberculosis was present
More than one co-morbid conditions were present in several patientsBMC Pulmonary Medicine 2006, 6:27 http://www.biomedcentral.com/1471-2466/6/27
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known regarding the clinical presentation and outcome of
AE-COPD in a predominantly bidi smoking population
similar to the patients included in the present study.
Observations from the present study indicate that patients
with AE-COPD had one or more co-morbid conditions
and metabolic abnormalities at presentation. High preva-
lence of past pulmonary TB was observed and active pul-
monary TB was identified to be an important infective
cause of AE-COPD.
Bidi smoking is more common in lower and middle
income groups especially those residing in smaller towns,
and rural areas of India as bidis are cheaper than ciga-
rettes. Furthermore, bidi smoking is considered to cause
about two to three times greater nicotine and tar inhala-
tion than do conventional cigarettes, due to the poor com-
bustibility of the bidi and greater puff frequency needed to
keep the bidi alight [11]. All these factors may exaggerate
the health risks associated with bidi smoke. The burden of
tobacco use is shifting from developed to developing
countries and it is generally believed that smoking habit is
on the rise in India [5,12]. Therefore, the prevalence of
COPD is expected to increase in the years to come and AE-
COPD is likely to be an important reason for ER visits in
India.
Clinical presentation of AE-COPD observed in the present
study (Table 2) was similar to that reported from studies
reported from other parts of the world [7,13-18]. Several
causes can contribute to altered sensorium in patients
with AE-COPD. These include, type II respiratory failure
and carbon dioxide narcosis, metabolic abnormalities
such as dyselectrolytemia, uremia and hepatic function
derangement among others. As these can be corrected, an
active attempt must be made to identify them when
patients present to the ER with AE-COPD. This is impor-
tant in developing countries like India because, majority
of the patients with AE-COPD seek emergency care at pri-
mary health centres, district hospitals and general hospi-
tals where facilities for round-the-clock laboratory
monitoring are seldom available. Unless these factors,
that are often correctable, are specifically sought and
checked, they may be missed. Thus, these factors not only
confuse the diagnosis but also contribute to mortality.
Majority of the patients in the present study had co-mor-
bid conditions (n = 53; 45.7%) (Table 1) and presence of
co-morbid factors was a predictor of death (Table 5) in
these patients. Co-morbid conditions can be a confusing
factor when assessing a patient with AE-COPD, as they
themselves can cause respiratory symptoms [19]. Further-
more, the co-morbid conditions can trigger AE-COPD and
their presence has been considered to be a predictor of
poor outcome in several studies [19]. In the present study,
patients who presented with AE-COPD who also had type
II diabetes mellitus and diabetic ketoacidosis (n = 3); type
II diabetes mellitus and active pulmonary TB (n = 5) died
suggesting that complications related co-morbid condi-
tions also contribute to the morbidity and mortality.
Therefore, accurate assessment of co-morbid conditions
and institution of specific treatment aimed against them
Table 2: Clinical presentation in 116 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to the 
medical intensive care unit
Variable %
Symptoms
Cough 100
Increased sputum volume 100
Increased sputum purulence 100
Recent rapid worsening of dyspnea 100
Accessory muscle use 60.3
Inability to complete a full sentence while talking 60.3
Pedal edema 19.8
Fever 29.3
Altered sensorium 12.9
Upper respiratory infection 08.6
Gastroesophageal reflux 07.8
Signs
Wheezing 100
Respiratory rate > 24/min 94.0
Crepitations 56.0
Cyanosis 33.6
Heart rate > 100/min 25.0
Elevated JVP 12.9
Systolic BP < 90 mm Hg 03.4
JVP = jugular venous pulseBMC Pulmonary Medicine 2006, 6:27 http://www.biomedcentral.com/1471-2466/6/27
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should also help in reducing the mortality in patients with
AE-COPD.
In the present study, compared with those who did not
develop AE-COPD, past history of pulmonary TB was
more frequently documented in patients presenting to the
ER with AE-COPD (p < 0.001). Furthermore, 28.4%
patients with AE-COPD admitted to the medical ICU had
evidence of past pulmonary TB and all males among them
were chronic smokers (Table 1). In a survey of 60000 men
aged 20 to 50 years [20], a definite correlation between
the incidence of pulmonary TB and smoking has been
documented. Gajalakshmi et al [21] observed that, among
urban men, the death rates from medical causes of ever
smokers were double those of never smokers. Of this
excess mortality among smokers, a third involved respira-
tory disease, chiefly TB (risk ratio ever to never smoked =
4.5) suggesting that smoking per se increased the inci-
dence of clinical TB. It has been suggested that nicotine
turns off the production of tumor necrosis factor-alpha
(TNF-α) by the macrophages in the lungs, and since TNF-
α is crucial for the maintenance of the latent state within
macrophages, reactivation may occur rendering the
patient more susceptible to the development of progres-
sive disease from latent M. tuberculosis infection [22].
Treated pulmonary TB is an important cause of COPD
[23] and has been reported in 41% [24] to 68% [25]
patients treated for pulmonary TB. Smoking seems to
increase the incidence of TB and prevalence of COPD is
high where smoking is highly prevalent,. Cavitation,
extensive fibrosis, bulla formation and bronchiectasis
have been implicated in the genesis of COPD caused by
destroyed lung due to treated pulmonary TB. Thus, in
areas such as India where pulmonary TB is highly endemic
and smoking is on the rise, the prevalence of COPD is
expected to increase and severe AE-COPD would become
a significant cause of morbidity and mortality in the ER.
This intriguing relationship between smoking, pulmonary
TB and COPD merits further study.
Five patients presenting with AE-COPD had type II diabe-
tes mellitus and sputum smear-positive pulmonary TB. In
the studies published from the west, there are scant refer-
ences to active pulmonary TB as an infective cause of AE-
Table 3: Laboratory abnormalities in 116 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to the 
medical intensive care unit
Variable %
Polycythemia (PCV >54% in men, >49% in women) 32.8
Leukocytosis [(>12 × 103/mm3), (>12 × 109/l)] 64.7
Neutrophilia [(> 70%), (> 0.7)] 77.6
Elevated ESR (>20 mm at the end of the first hour) 64.7
Hypoalbuminemia [(< 3.5 g/dl), (< 35 g/dl)] 19.0
Hyponatremia [serum sodium < 120 meq/l, (< 120 mmol/l)] 16.4
Hypokalemia [serum potassium < 3.5 meq/l, (< 3.5 mmol/l)] 16.4
Hyperbilirubinemia [(>1.2 mg/dl), (> 20.5 μmol/l)] 06.0
Elevated transaminases [>50 IU/l] 22.4
Elevated blood urea [(>50 mg/dl), (>17.9 mmol/l)] 45.7
Elevated serum creatinine [(>1.5 mg/dl), (> 132.6 μmol/l)] 19.0
ESR = erythrocyte sedimentation rate
Table 4: Predictors of outcome in 116 patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring 
admission to the intensive care unit: univariate sensitivity analysis
Variable χ2 p-value
Presence of co-morbid illness 1.673 0.0196
Altered consciousness 3.65 0.056
Presence of tachycardia 9.605 0.002
Peripheral edema 1.9 0.168
Hypoalbuminemia 4.3 0.038
Elevated transaminases 4.2 0.035
Acidosis 10.257 0.001
Arterial hypoxemia 4.999 0.025
Hypercapnia 2.189 0.139
Presence of new infiltrates on the chest 
radiograph
5.24 0.017
Need for invasive ventilation 16.178 0.0001BMC Pulmonary Medicine 2006, 6:27 http://www.biomedcentral.com/1471-2466/6/27
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COPD at the time of presentation to the ER [7,13-18,26].
This observation is particularly relevant to countries
where TB is highly endemic. Patients with open TB in
whom the diagnosis of TB is not considered due to low
threshold of suspicion constitute a health hazard not only
to the treating physicians in the ER, but also to the nursing
and paramedical personnel. These observations merit fur-
ther evaluation.
Lack of uniform definition of AE-COPD hampers interna-
tional comparisons and the evolution of uniform diag-
nostic testing and treatment guidelines [19]. Furthermore,
initial evaluation of a patient in the ER in the guidelines
issued by several international organisations are also dif-
ferent [27,28]. The recently published Indian guidelines
deal with AE-COPD only briefly [29]. Guidelines for the
initial diagnostic evaluation of AE-COPD should facilitate
differentiating AE-COPD from other conditions which
can mimick it such as congestive heart failure, pneumoth-
orax, pleural effusion, pulmonary embolism and arrhyth-
mias. With the evolution of a consensus definition [19],
these differences are likely to be resolved.
Several studies have attempted to identify the predictors
of poor outcome in patients with AE-COPD [7,13-18,26].
However, there has been no such study published from
India to the best of our knowledge. Acute respiratory fail-
ure is a common reason for admission into the ICU in
patients with AE-COPD [7,13-18,26]. We also observed
that need for mechanical ventilation was associated with
a poor prognosis (Table 5). The study was carried out at
our tertiary care teaching institute with facilities for inva-
sive monitoring and assisted mechanical ventilation.
These facilities are not widely available and affordable in
most of the Rayalaseema area of Andhra Pradesh and
majority of patients needing assisted ventilation are
referred here often, late in the course of their disease. This
could be the reason for reason for the high prevalence of
respiratory failure in these patients. In order to cope up
with the expected increase in the burden of AE-COPD,
there is a pressing need for making tertiary care facilities
widely available and affordable in developing countries
like India.
In conclusion, in addition to the host genetic factors
genetic factors, smoking behaviour, accessibility to health
care and presence of co-morbid conditions contribute to
morbidity and mortality due to AE-COPD. Correction of
metabolic abnormalities such as dyselectrolytemia and
judicious use of empirical antimicrobial treatment will
also help in reducing the mortality. Large scale nation-
wide multicentric studies are required to clarify these
issues and evolve consensus guidelines. Further research is
required to clarify the association between pulmonary TB
and COPD.
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